Close Menu

NEW YORK (GenomeWeb) – Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment.

The trial, called Breast Cancer Response Evaluation for Individualized Therapy (BREVITY), involves investigators from five countries and aims to enroll over 700 patients from 40 centers over the next two years.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.